In August 2026, a cancer patient shared an Instagram reel built on an old Australian television report, reigniting global interest in a rainforest seed drug. The post promised a universal cure derived from the blushwood berry, a claim that has circulated online for years but stands in stark contrast to the current clinical data. The reality, according to the latest trial reports, is more nuanced: tigilanol tiglate is not a systemic cure for all cancers, but a targeted intratumoural agent showing strong local results in specific solid tumours.
From Rainforest to Regulatory Approval
Tigilanol tiglate, also known by its development code EBC-46, is a small molecule extracted from the seeds of the blushwood tree. This tree is native to the rainforests of north Queensland, Australia. The company developing the drug, QBiotics, has spent years translating this natural compound into a clinical treatment. The history of the drug is not without controversy, as older media reports often overstated its potential, leading to public confusion about whether eating the berry or taking oral supplements could treat cancer. The scientific consensus is clear: consuming the berry does nothing to treat cancer. The active pharmaceutical ingredient is only effective when administered as a direct injection into the tumour mass.
Despite the mixed public perception, the drug has achieved a significant regulatory milestone. Tigilanol tiglate is FDA-approved for veterinary use under the brand name Stelfonta. It is indicated for the treatment of non-metastatic mast cell tumours in dogs. According to QBiotics, the drug demonstrated approximately 75% complete resolution of tumours in dogs after a single injection. This approval in veterinary medicine provided the safety and efficacy foundation necessary to advance the drug into human clinical trials. In February 2024, the U.S. Food and Drug Administration granted tigilanol tiglate orphan drug designation, recognizing its potential to treat rare diseases in humans.
How the Injection Works
The mechanism of action for tigilanol tiglate is local rather than systemic. It is administered as an intratumoural injection, meaning the drug is physically inserted directly into the cancerous tissue. This approach is distinct from chemotherapy or immunotherapy, which circulate through the bloodstream to reach cancer cells anywhere in the body. By injecting the drug directly into the tumour, clinicians aim to achieve high concentrations of the active agent at the site of the disease while minimizing exposure to healthy tissues elsewhere in the body.
This local mode of action explains the safety profile observed in trials. According to QBiotics, the drug was generally well tolerated in human studies. Most adverse events were consistent with the expected local reaction to an injection, including pain, swelling, and necrosis at the injection site. No new safety signals were identified in the early human trials. Because the drug acts locally, the side effects are confined to the area of the injection, which is a significant advantage for patients who have already undergone extensive systemic treatments that may have compromised their overall health.
What the Human Trial Data Shows
The current human data comes from a series of small, rapid Phase II clinical trials designed to evaluate the drug’s therapeutic potential across multiple solid tumour indications. The most recent data, published in mid-2025, focuses on soft tissue sarcoma (STS), a rare and aggressive cancer that forms in connective tissues. In 2023, there were approximately 128,000 new cases of STS globally, with incidence rates growing by 0.54% per year. These patients often face limited treatment options, making the trial results particularly noteworthy.
In Stage 1 of the Phase IIa trial QB46C-H07, researchers evaluated tigilanol tiglate in 11 patients, 10 of whom were evaluable for response. The primary endpoint was the Objective Response Rate (ORR) in injected tumours. According to the filing, an ORR of 80% was achieved. This means that 8 out of 10 evaluable patients saw either complete ablation (a 100% reduction in tumour volume) or partial ablation (a reduction of at least 30% in volume) of the treated tumours. At the tumour level, 22 of the 27 injected tumours across all patients showed complete or partial ablation. Specifically, 14 tumours achieved complete ablation, and 8 showed partial ablation.
A critical aspect of the data is the durability of these responses. None of the 14 tumours that achieved complete ablation recurred at the six-month follow-up mark. This suggests that the drug may provide long-term benefit for patients whose tumours respond to the injection. The trial was conducted at Memorial Sloan Kettering Cancer Center in New York, with Dr. Edmund Bartlett serving as the Principal Investigator. Following these positive results, the decision was made to expand the trial. Stage 2 dosing began in September 2025, with the first three patients treated in the expansion arm. This stage aims to build on the encouraging response rates and includes new objectives to evaluate the effect of the drug on overall disease control, not limited to injected tumours.
Similar results have been seen in other cancer types. In a Phase II trial QB46C-H08 for head and neck solid malignancies, tigilanol tiglate achieved a 78% Objective Response Rate in injected tumours. This trial focused on patients who were refractory to standard of care, meaning their cancer had stopped responding to conventional treatments. The results, based on 14 responses across 18 injected tumours, highlight the potential for local tumour control in a population with few options. Professor Kevin Harrington of the Royal Marsden Cancer Hospital in London, the lead Principal Investigator, noted that the early experience has been highly encouraging, particularly in difficult-to-treat forms of the disease.
Limitations and Patient Guidance
While the response rates are high, it is essential to understand the limitations of the current data. The trials are small in scale, involving only a dozen or so patients per stage. The results are strictly limited to the injected tumours. The drug has not been shown to cure cancer throughout the body, nor has it been approved for human use. The viral social media posts that claim the drug is a universal cancer cure go beyond the scientific data. The drug is a local treatment, not a systemic one.
Furthermore, the current trials do not yet provide long-term survival data. The six-month follow-up in the soft tissue sarcoma trial is a positive sign for durability, but longer-term studies are needed to confirm these benefits. The Stage 2 trial is also exploring whether the drug can re-sensitise patients to systemic therapies to which they were previously unresponsive, but this is still an exploratory objective. Patients should be cautious of claims that the drug is a “miracle” or “breakthrough” cure. The data shows promising local control in specific cancers, but it is not a replacement for standard oncology care.
For patients considering this treatment, the next step is to consult with their oncologist. The drug is currently available in clinical trials for specific indications. Patients should ask their doctors about eligibility for ongoing trials, such as the Stage 2 soft tissue sarcoma study or other solid tumour trials. Understanding the local nature of the treatment and the specific cancer type is crucial. The blushwood berry itself has no therapeutic value; only the processed pharmaceutical compound, administered by medical professionals, has shown efficacy. As the trials progress, more data will emerge, but for now, the evidence supports a targeted, local approach rather than a broad, curative one.
Sources
- QBiotics reports 80% objective response rate in injected tumours in Stage 1 of Phase IIa clinical trial of tigilanol tiglate for Soft Tissue Sarcoma
- QBiotics reports 78% overall response rate in injected tumours treated with tigilanol tiglate in a Phase II head and neck cancer clinical trial
- Promising Efficacy for Tigilanol Tiglate in Advanced Soft Tissue Sarcoma | Targeted Oncology – Immunotherapy, Biomarkers, and Cancer Pathways
- First three patients dosed in Stage 2 of Phase IIa clinical trial of tigilanol tiglate in Soft Tissue Sarcoma
Photo: Linda Bartlett (Photographer) (Public domain)
